CYP2C19*2 polymorphism in Polish peptic ulcer patients.

[1]  M. Pirmohamed,et al.  CYP2C19*17 Gain‐of‐Function Polymorphism Is Associated With Peptic Ulcer Disease , 2013, Clinical pharmacology and therapeutics.

[2]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[3]  Yoshiro Saito,et al.  Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. , 2012, Drug metabolism and pharmacokinetics.

[4]  Y. Cao,et al.  Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. , 2011, Genetics and molecular research : GMR.

[5]  G. Lee,et al.  The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. , 2010, Gut and liver.

[6]  Y. Yamaji,et al.  A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer , 2010, Journal of Gastroenterology.

[7]  W. Marlicz,et al.  Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole , 2010, European Journal of Clinical Pharmacology.

[8]  H. Akkız,et al.  Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication. , 2010, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[9]  R. Totah,et al.  Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology , 2009, Expert opinion on drug metabolism & toxicology.

[10]  Myung-Gyu Choi,et al.  Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin , 2009, Journal of gastroenterology and hepatology.

[11]  K. Zhao,et al.  Prevalence of Peptic Ulcer in Dyspeptic Patients and the Influence of Age, Sex, and Helicobacter pylori Infection , 2008, Digestive Diseases and Sciences.

[12]  Y. Goto,et al.  Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. , 2006 .

[13]  T. Starzynska,et al.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients , 2006, European Journal of Clinical Pharmacology.

[14]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[15]  H. Sugimura,et al.  Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection , 2005, Alimentary pharmacology & therapeutics.

[16]  K. Safranow,et al.  Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection , 2005, European Journal of Clinical Pharmacology.

[17]  J. Schabowski,et al.  Peptic ulcer among rural population in a selected region of south-eastern Poland. , 2004, Annals of agricultural and environmental medicine : AAEM.

[18]  A. Caputi,et al.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. , 2004, Pharmacological research.

[19]  Shu-qing Chen,et al.  Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. , 2004, World journal of gastroenterology.

[20]  J. Brockmöller,et al.  Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population , 2003, European Journal of Clinical Pharmacology.

[21]  F. Perna,et al.  The clinical role of cytochrome p450 genotypes in Helicobacter pylori management , 2003, American Journal of Gastroenterology.

[22]  S. Ishihara,et al.  CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole , 2000, Alimentary pharmacology & therapeutics.

[23]  A. Ohnishi,et al.  Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. , 2000, Life sciences.

[24]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[25]  T. Arakawa,et al.  Arachidonic acid cascade and gastric mucosal injury, protection, and healing: topics of this decade. , 1995, Journal of clinical gastroenterology.

[26]  P. Sipponen,et al.  Peptic ulcer and chronic gastritis: their relation to age and sex, and to location of ulcer and gastritis. , 1990, Gastroenterologie clinique et biologique.